



Newest technologies
for a healthier world

CAMPTON Biochip Reader is taking POC diagnostics to the next level in lab testing

At CAMPTON Diagnostics we believe that faster and more accessible diagnostics will improve patient outcomes leading to a longer and healthier life. With the new CAMPTON Reader 100 a true point-of-care platform is introduced enabling while-you-wait results for enhanced disease treatment and management.

Our technology and approach

The CAMPTON Reader 100 platform is a fully automated point-of-care-system comprised of the assay module and the cartridge with the integrated patented electrical biochip technology. This system allows the detection of multiple biomarkers in two different modes: serological assays and nucleic acid amplification technology based / molecular biological assays.

Serological assays detect biomarkers in just a few microlitres of serum or whole blood within a few minutes using an enzyme-linked immunosorbent assay (ELISA) directly on a gold electrode array whereas nucleic acid amplification technology based assays detect biomarkers in a variety of specimen including nasopharyngeal samples, saliva and whole blood via isothermal nucleic acid amplification for example.

Advantages of the new CAMPTON Biochip-Reader-System

Common diagnostic tests usually require laboratories and excessive equipment as well as extensively trained personnel to deliver results in slow and time-consuming processes (e.g. 1-3 days to get results).

Portable diagnostic devices like the CAMPTON Reader 100 overcome those restrictions: The fully automated platform performs sample extraction, preparation, (amplification*) and detection all within the self-contained single-use "laboratory in a cartridge" making it especially easy to perform with minimal equipment and training.

The CAMPTON Reader 100 provides rapid test results within minutes, enabling cost and time-effective diagnostics. The consolidated assay design allows the testing for both serological and molecular biological assays reducing the need for multiple testing platforms. In contrast to competitors who often use optics to detect the test results, our newly developed CAMPTON technology uses electrical signals, making the CAMPTON Reader 100 technology more robust and therefore suitable for the use in nearly any climate and even in the most remote places.

CAMPTON Biochip Reader helps to improve patient care and treatment.

With just a few microlitres of blood, our Biochip Reader delivers reliable and fast diagnosis on a wide variety of diseases.

* For molecular biological assays an additional sample purification and manual handling step may be required.

CAMPTON READER 100



CAMPTON Reader 100 - at a glance

- Fully automated – from sample-in to automatically analysed and recorded results on demand
- Robust – works over broad operating conditions
- Easy – minimal equipment and training required
- Smart Handling – specifically shaped ready-to use cartridges are especially user-friendly and enable easy loading of all consumables
- Safe – sealed cartridges help prevent cross-contamination
- Compact Design – space efficient and true POC capabilities



Possible applications for the Biochip system

Next to the wide range of possible customized applications, the following established tests are currently available including all required assay reagents in ready-to-use-kits for the biochip system:

- SARS-CoV-2 (serological)
- Vaccination Status (serological)
- CRP (serological)
- Customer specific tests

CAMPTON Diagnostics delivers innovative assays on an easy-to-use platform for point-of-care diagnostics. We are committed to expand our test menu to cover more infectious diseases and biomarkers with current testing panels in pipeline:

Covid-19 (serological and molecular biological) and MRSA (molecular biological), both expected to be released in 2020/2021.

Our first product is focused on the aforementioned tests – but we can quickly address any disease detected from antibodies, DNA or RNA!

The volume production of the first reader version is planned to start in Q4 2020 and a miniaturized reader version for enhanced mobile diagnostics is already under development.

About CAMPTON Diagnostics GmbH

Spun off from the Fraunhofer Institute for Silicon Technology (ISIT) in Itzehoe in 2016, the company develops and markets complete measuring systems for point-of-care diagnostics, i.e. for on-site examinations of patients. CAMPTON Diagnostics combines biotechnological and engineering know-how under one roof.

CAMPTON Diagnostics is based in Itzehoe and has a strategic technology partnership with the Fraunhofer Institute for Silicon Technology (ISIT). One of the shareholders of CAMPTON is the German Würth Group.

CAMPTON Diagnostics GmbH

Fraunhoferstr. 3
25524 Itzehoe / Germany
T: +49 4821 14889-0
E-Mail: info@campton-diagnostics.com

www.campton-diagnostics.com